Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bill.com Holdings Inc (BILL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bill.com Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Bill.com Holdings Inc trades at $49.45 (market cap $4.93B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6× Bill.com Holdings Inc's market cap, and Bill.com Holdings Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BILL | |
|---|---|---|
Market Cap | $29.60B | $4.93B |
Sector | Health | Technology |
52-Week High | $491.22 | $56.32 |
52-Week Low | $205.48 | $31.96 |
Enterprise Value | $27.56B | $4.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
BILL Holdings trades at $48.63, down 1.28% on the day, with a bullish technical signal from moving averages and positive earnings beats in recent quarters. Revenue growth is strong, reaching $1.46B in 2025, but profitability remains thin with a net income margin of just 0.01%. The company is focusing on AI-driven automation and operational efficiency, including a recent 30% workforce reduction and new executive appointments to spur growth.
Outlook is cautiously optimistic given analyst consensus favoring Buy ratings (56%) and a price target implying modest upside. Key risks include intense fintech competition and the challenge of translating high revenue into sustained profitability. Cash flow trends show improvement, but investors should monitor execution on margin expansion and competitive positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →
